297 related articles for article (PubMed ID: 31206982)
1. Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta-analysis of controlled studies.
Appenzeller-Herzog C; Mathes T; Heeres MLS; Weiss KH; Houwen RHJ; Ewald H
Liver Int; 2019 Nov; 39(11):2136-2152. PubMed ID: 31206982
[TBL] [Abstract][Full Text] [Related]
2. Current Drug Managements of Wilson's Disease: From West to East.
Li WJ; Chen C; You ZF; Yang RM; Wang XP
Curr Neuropharmacol; 2016; 14(4):322-5. PubMed ID: 26639459
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
[TBL] [Abstract][Full Text] [Related]
4. Concomitant immune-related events in Wilson disease: implications for monitoring chelator therapy.
Seessle J; Gotthardt DN; Schäfer M; Gohdes A; Pfeiffenberger J; Ferenci P; Stremmel W; Weiss KH
J Inherit Metab Dis; 2016 Jan; 39(1):125-30. PubMed ID: 26067812
[TBL] [Abstract][Full Text] [Related]
5. Switching Pharmacological Treatment in Wilson Disease: Case Report and Recommendations.
Leung M; Wu Lanzafame J; Medici V
J Investig Med High Impact Case Rep; 2020; 8():2324709619896876. PubMed ID: 31920114
[No Abstract] [Full Text] [Related]
6. Zinc Therapy for Wilson Disease in Children in French Pediatric Centers.
Santiago R; Gottrand F; Debray D; Bridoux L; Lachaux A; Morali A; Lapeyre D; Lamireau T
J Pediatr Gastroenterol Nutr; 2015 Dec; 61(6):613-8. PubMed ID: 26230903
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Wilson's disease: what are the relative roles of penicillamine, trientine, and zinc supplementation?
Schilsky ML
Curr Gastroenterol Rep; 2001 Feb; 3(1):54-9. PubMed ID: 11177695
[TBL] [Abstract][Full Text] [Related]
8. Wilson disease - currently used anticopper therapy.
Członkowska A; Litwin T
Handb Clin Neurol; 2017; 142():181-191. PubMed ID: 28433101
[TBL] [Abstract][Full Text] [Related]
9. Practical recommendations and new therapies for Wilson's disease.
Brewer GJ
Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and treatment of Wilson's disease.
Subramanian I; Vanek ZF; Bronstein JM
Curr Neurol Neurosci Rep; 2002 Jul; 2(4):317-23. PubMed ID: 12044251
[TBL] [Abstract][Full Text] [Related]
11. [Wilson disease: an update].
Seo JK
Korean J Hepatol; 2006 Sep; 12(3):333-63. PubMed ID: 16998287
[TBL] [Abstract][Full Text] [Related]
12. [Wilsons disease].
Mareček Z; Brůha R
Vnitr Lek; 2013 Jul; 59(7):578-83. PubMed ID: 23909262
[TBL] [Abstract][Full Text] [Related]
13. Wilson disease.
El-Youssef M
Mayo Clin Proc; 2003 Sep; 78(9):1126-36. PubMed ID: 12962167
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.
Brewer GJ; Askari F; Lorincz MT; Carlson M; Schilsky M; Kluin KJ; Hedera P; Moretti P; Fink JK; Tankanow R; Dick RB; Sitterly J
Arch Neurol; 2006 Apr; 63(4):521-7. PubMed ID: 16606763
[TBL] [Abstract][Full Text] [Related]
15. Response to different therapeutic approaches in Wilson disease. A long-term follow up study.
Rodríguez B; Burguera J; Berenguer M
Ann Hepatol; 2012; 11(6):907-14. PubMed ID: 23109455
[TBL] [Abstract][Full Text] [Related]
16. The treatment of Wilson's disease, a rare genetic disorder of copper metabolism.
Purchase R
Sci Prog; 2013; 96(Pt 1):19-32. PubMed ID: 23738435
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of Wilson disease].
Smolarek C; Stremmel W
Z Gastroenterol; 1999 Apr; 37(4):293-300. PubMed ID: 10378366
[TBL] [Abstract][Full Text] [Related]
18. Trientine induced colitis during therapy for Wilson disease: a case report and review of the literature.
Boga S; Jain D; Schilsky ML
BMC Pharmacol Toxicol; 2015 Nov; 16():30. PubMed ID: 26589720
[TBL] [Abstract][Full Text] [Related]
19. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial.
Schilsky ML; Czlonkowska A; Zuin M; Cassiman D; Twardowschy C; Poujois A; Gondim FAA; Denk G; Cury RG; Ott P; Moore J; Ala A; D'Inca R; Couchonnal-Bedoya E; D'Hollander K; Dubois N; Kamlin COF; Weiss KH;
Lancet Gastroenterol Hepatol; 2022 Dec; 7(12):1092-1102. PubMed ID: 36183738
[TBL] [Abstract][Full Text] [Related]
20. Long-term evaluation of urinary copper excretion and non-caeruloplasmin associated copper in Wilson disease patients under medical treatment.
Pfeiffenberger J; Lohse CM; Gotthardt D; Rupp C; Weiler M; Teufel U; Weiss KH; Gauss A
J Inherit Metab Dis; 2019 Mar; 42(2):371-380. PubMed ID: 30746719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
